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Extracorporeal Membrane Oxygenation as a
Bridge to Chimeric Antigen Receptor T-cell
Therapy for Severe Refractory Sepsis in the
Setting of Relapsed Refractory Pediatric Acute
Lymphoblastic Leukemia: A Case Report
Alyssa Stoner, MS, DO1; Jenna O. Miller, MD1; Terrie Flatt, DO2; Jessica S. Wallisch, MD1

Background: Pediatric oncology patients with sepsis are at higher
risk of morbidity and mortality compared with pediatric patients without malignancy. Historically, patients with relapsed and/or refractory
disease were not considered candidates for aggressive life support
strategies including extracorporeal membrane oxygenation support.
Case Summary: We report a 4-year-old female with relapsed refractory pre-B cell acute lymphoblastic leukemia preparing for chimeric
antigen receptor T cell therapy with tisagenlecleucel who was admitted with fever and neutropenia. She progressed to refractory septic shock secondary to Escherichia coli bacteremia and required
escalation of hemodynamic support to venoarterial extracorporeal
membrane oxygenation cannulation. She cleared her E. coli bacteremia, was decannulated, subsequently received her chimeric antigen
receptor T-cell therapy, and was declared disease free 1 month from
her initial presentation.
Conclusion: The ability to provide chimeric antigen receptor T-cell
therapy at designated institutions can augment extracorporeal membrane oxygenation candidacy discussions in oncology patients with
relapsed disease and may make extracorporeal membrane oxygenation candidacy for oncology patients with refractory sepsis more
favorable.
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P

ediatric oncology patients with sepsis are at higher risk of
morbidity and mortality as compared to pediatric patients
without malignancy. The increased risk of severe infection
and sepsis in the setting of neutropenia has been well documented,
especially in the presence of an indwelling central catheter (1–5).
Historically, oncologic patients, especially those with active disease, have not been considered optimal candidates for extracorporeal membrane oxygenation (ECMO) support, although sepsis
itself is an accepted indication for ECMO (6). However, new treatment modalities have become available to patients with relapsed
and refractory leukemia, including chimeric antigen receptor
T-cell (CAR T-cell) therapy, which has transformed the disease
course and survival rates of a once incurable disease (7).
We present the following case report as an example of ECMO
for refractory pediatric septic shock and multiple organ failure in
a patient with relapsed refractory acute lymphoblastic leukemia
(ALL) undergoing lymphodepletion for CAR T-cell therapy.
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PRESENTING CONCERNS AND CLINICAL
FINDINGS

The patient was a 4-year-old Mexican female with a history of
relapsed refractory pre-B cell ALL, who transferred her care to our
facility to facilitate CAR T-cell therapy.
Past medical history was pertinent for the diagnosis of standard risk pre-B ALL with blasts that coexpressed CD19, CD22,
CD58, CD10, CD38, and cytogenetics that revealed p53 deletion, t(1;19) with a complex karyotype. She had no CNS disease.
Patient was treated with the National Mexican Protocol (based
off Berlin-Frankfurt-Münster and St. Jude Total XIII). There was
www.ccejournal.org
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no evidence of morphologic or minimal residual disease via flow
cytometry at the end of induction chemotherapy. She relapsed
199 days after diagnosis then failed reinduction chemotherapy
as well as two cycles of blinatumomab. She was then treated with
reinduction therapy per ALL R3 and did not achieve remission.
She experienced a high burden of extramedullary disease in the
liver, spleen, kidneys, lymph nodes, and a chloroma to left orbit
causing a significant cranial nerve II palsy. She experienced renal
insufficiency requiring long-term electrolyte replacement. Due to
poor response to therapy, plans were made for transfer of care for
CAR T-cell therapy. She received bridging oral chemotherapy with
6-mercaptopurine and methotrexate.
Approximately 2 weeks prior to presentation to the ICU, she
was treated for a Staphylococcal epidermidis central catheter
infection and septic shock with a 10-day course of vancomycin.
In preparation for CAR T-cell infusion, she received lymphoid
depleting chemotherapy that consisted of fludarabine and cyclophosphamide. She presented to the emergency department on
day 2 of lymphoid depleting therapy (1 wk prior to planned CAR
T-cell treatment) with fever, nausea, headache, and fatigue. After
initial resuscitation, work-up, and initiation of broad-spectrum
antibiotics for fever with neutropenia, she was admitted to the
hematology/oncology team.
Approximately 36 hours after admission, she was transferred
to the PICU due to progressive septic shock with hypotension. On
examination, she was afebrile, blood pressure was 69/31, heart rate
165 beats per minute, respiratory rate 56 breaths per minute, and
oxygen saturation was 100% on room air. Poor perfusion and a
capillary refill time of 5 seconds were noted. Pulses were noted
to be 3+ in bilateral radial arteries. Despite tachycardia, no murmur or gallop was appreciated. She remained hypotensive despite
aggressive fluid resuscitation (100 mL/kg normal saline over
24 hr), high doses of inotropes, and broad-spectrum antibiotics.
She underwent intubation for persistent shock within an hour of
PICU transfer. At this time, author (J.O.M.) contacted the patient’s
oncology team to discuss expected prognosis with her upcoming
CAR T-cell therapy and gain initial impressions of her ECMO
candidacy.

DIAGNOSTIC FOCUS AND ASSESSMENT

Her blood culture was found to be positive for Escherichia coli,
which was suspected to be multidrug resistant based on preliminary sensitivity profile and history of prolonged care in
Mexico, which complicated her antibiotic management. She
was maintained on minimal respiratory support with mechanical ventilation with good oxygenation and ventilation. An initial
echocardiogram obtained following PICU transfer revealed severe
global hypokinesis of the left ventricle with an ejection fraction
(EF) of 31% while on significant vasoactive support including
epinephrine, norepinephrine, and vasopressin with maximal
Vasoactive-Inotropic Score of 98. With an ongoing shock state and
acute kidney injury including severe oliguria and total body fluid
overload (18%), in addition to lack of response to escalation of
vasoactive support, stress dose steroids, bicarbonate infusion, and
continuous renal replacement therapy (CRRT) were initiated. At
8 hours after CRRT initiation, there was evidence of progression
2
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to multiple organ dysfunction with ongoing shock (peak lactate of
24 mmol/L), myocardial ischemia (troponin 2.03 nanogram/mL),
renal dysfunction (three-fold rise in baseline serum creatinine
0.2–0.6), coagulopathy (prothrombin time 28.6 s, partial thromboplastin time 111.2 s, international normalized ratio 2.50), and
hepatobiliary dysfunction (aspartate aminotransferase 224 unit/L,
total bilirubin 4.3 mg/dL, direct bilirubin 3.7 mg/dL) (Fig. 1).
With this ongoing decline despite escalation of support, conversations continued between the pediatric intensivist (J.S.W.) and
her primary oncologist (T.F.) as to her ECMO candidacy and prognosis in the setting of her relapsed refractory ALL. With our institution’s experience and success with CAR T-cell therapy, it was felt
the patient’s survival was estimated to be greater than 50% with
respect to her underlying disease, and the family was consented
for venoarterial ECMO with the aid of a Spanish interpreter.

THERAPEUTIC FOCUS AND ASSESSMENT

The patient was cannulated in the PICU for venoarterial ECMO
with a 16F arterial cannula in the right common carotid and 21F
venous cannula in the right internal jugular vein with confirmation of positioning on echocardiography, using flows of 140 mL/
kg/min. During cannulation, her indwelling central catheter was
removed for infectious source control. Anticoagulation was managed with systemic heparin initially with lower targets due to catheter removal and subsequently escalated to goal activated clotting
time 160–180 seconds and anti-Xa level 0.5–0.7 IU/mL without
bleeding or thrombotic complications. CRRT via Prismaflex and
therapeutic plasma exchange (TPE, 1.5× volume day 1 followed by
1× volume for a total of 5 d) were immediately used in tandem
with the ECMO circuit for refractory sepsis with multiple organ
dysfunctions. Broad-spectrum antimicrobial therapy to cover her
confirmed extended spectrum beta-lactamase producing E. coli
included meropenem, ceftazidime/avibactam, gentamicin, and
micafungin.

FOLLOW-UP AND OUTCOMES

Following ECMO cannulation, she was rapidly weaned off the
previously mentioned vasoactive and inotropic support. She was
initiated on milrinone for afterload reduction and improvement
in systemic vascular resistance. As she maintained good antegrade
flow across the aortic valve, she did not require left atrial decompression. Her bacteremia cleared, and the cardiac dysfunction
quickly improved with repeat echo demonstrating low normal
biventricular systolic function with an EF of 51% during an ECMO
clamp trial after 120 hours of ECMO. She was decannulated following a total of 124 hours on venoarterial ECMO (PICU day 6)
and extubated on PICU day 10. With recovery of organ dysfunction, she received her CAR T-cell infusion (tisagenlecleucel) on
PICU day 17 and was then transferred to the hematology/oncology service. She developed cytokine release syndrome requiring
tocilizumab and brief PICU readmission. She was identified to be
in remission 1 month later and was discharged from the hospital
shortly thereafter.
2020 • Volume 2 • e0093
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Figure 1. Patient transferred to the PICU on hospital day 2 and subsequently initiated on venoarterial extracorporeal membrane oxygenation (VA ECMO)
on PICU day 2, decannulated on PICU day 6, and extubated on PICU day 10. To support her multiple organ dysfunction, she was initiated on continuous
venovenous hemodialysis (CVVHD) the evening prior to VA ECMO cannulation and remained on continuous renal replacement therapy (CRRT) through
decannulation. In addition, she received therapeutic plasma exchange (TPE) for a total of five treatments. Her cardiac function improved, and she was
able to receive her chimeric antigen receptor T-cell (CAR T-cell) infusion. She remained in the hospital for ongoing monitoring related to her treatment
with a short return to the PICU for cytokine release syndrome. Repeat bone marrow biopsy deemed her disease free, and she was discharged 10 wk after
admission. ALL = acute lymphoblastic leukemia, CN II = cranial nerve two, CVVHF = continuous venovenous hemo filtration, E. coli MDRO = Escherichia
coli multidrug-resistant organism, EF = ejection fraction, MRD = minimal residual disease.

DISCUSSION

Patients with active relapsed and/or refractory ALL have previously not been considered optimal candidates for ECMO, and
interpretation of the ELSO Red Book would at best consider this
situation as a relative contraindication due to the presence of a
preexisting chronic illness with low survival rate and at worst
an absolute contraindication due to incurable malignancy (8).
Yet, this very population is at notably higher risk for increased
morbidity and mortality in the face of sepsis, often requiring a
higher intensity of therapy and interventions (9–13). Additionally,
ECMO has been successfully used in patients with active curable
malignancy for a variety of indications (14–17).
New cancer treatment modalities have become available for
relapsed refractory pre-B ALL, including CAR T-cell therapy, that
have transformed the disease course and survival rates of what
was once an incurable disease. Pediatric CAR T-cell clinical trials
have reported 81%–93% complete remission and 52%–79% overall 12-month survival (7). Additionally, experience with ECMO
in refractory sepsis is increasing, and survival rates for this rescue
modality are approaching those for refractory respiratory failure
at 50%–60% in recent years (18–25).
Although our patient had maximized the supports as outlined in the American College of Critical Care Medicine
Clinical Practice Parameters for Hemodynamic Support of
Pediatric and Neonatal Septic Shock, she continued to have
Critical Care Explorations

progressive refractory shock with concern for impending cardiac arrest (6). She had already undergone harvest of T-cells
and was undergoing lymphoid-depleting therapy in preparation
for CAR T-cell therapy; thus, the time course to her definitive
therapy was short, and her estimated prognosis with this therapy was significantly higher and above the threshold set by the
Extracorporeal Life Support Organization as a contraindication
for ECMO. Additionally, she was at a quaternary care center with
the resources and experience for both ECMO and CAR T-cell
therapy.
Certainly, there are ongoing patient-centric and center-centric
limitations to this consideration and approach. One serious initial consideration for our patient was the possibility of anthracycline-induced cardiac dysfunction which has been associated
with higher intensity treatment and mortality (26). As this would
have altered the expected recovery and survival, it is an important
consideration; our patient was ultimately deemed to have a lower
likelihood of this complication with normal recent preadmission
echo reports. Additionally, as sepsis tends to be a more rapidly
reversible etiology with shorter ECMO runs, this rationale may
not be applicable to other indications for ECMO cannulation and
support. Finally, had our patient not had plans for and/or begun
preparatory stages of CAR T-cell therapy, the expected survival
would likely have precluded the use of ECMO.
www.ccejournal.org
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We propose that as more novel and targeted therapies such as
CAR T-cell therapy become available, that the contraindications
for aggressive life support strategies in our oncology patients may
need to be modified or re-examined on a case-by-case basis.

CONCLUSIONS

The ability to provide CAR T-cell therapy at designated institutions
can augment ECMO candidacy discussions in oncology patients
with relapsed disease. CAR T-cell therapy can improve survival
from underlying relapsed disease and may make ECMO candidacy for oncology patients with refractory sepsis more favorable.
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